Paclitaxel nanoparticles - Onxeo

Drug Profile

Paclitaxel nanoparticles - Onxeo

Alternative Names: Paclitaxel-Transdrug

Latest Information Update: 03 Sep 2014

Price : $50

At a glance

  • Originator BioAlliance Pharma
  • Developer Onxeo SA
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 03 Sep 2014 Discontinued - Preclinical for Solid tumours in France (PO)
  • 21 Feb 2007 Preclinical development is ongoing
  • 28 May 2005 Preclinical trials in Solid tumours in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top